UA-93693832-1skip to primary navigationskip to content

News

Site News

Capella Topping Out Ceremony

last modified Apr 26, 2017 12:04 PM
The Capella Topping Out Ceremony was held on Friday, and here you can see Cambridge University Vice-Chancellor Leszek Borysiewicz finishing off the final concrete pour.

The Milner Therapeutics Institute will have research laboratories within the Capella Building, which is on the Cambridge Biomedical Campus. The laboratories will be operational in 2018 and will house research groups from the Cambridge research community. A research facility will also be established, accessible to the wider research community as part of the outreach programme. The facility is envisaged to house robotics for customised drug screening as well as gene editing and bioinformatics support.

Topping OutTopping Out2

New Partnership with US pharmaceutical company, Pfizer

last modified Jan 19, 2017 07:44 AM
Press Release Cambridge, 19 January 2017 – The Milner Therapeutics Institute announces Pfizer as a new partner joining the Consortium to develop mutually-beneficial collaborations with Cambridge academics and the Milner Therapeutics Institute.

Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune and Otsuka in the Milner Therapeutics Consortium

Major research investment to work with academic scientists in Cambridge

Cambridge, 19 January 2017 – The Milner Therapeutics Institute today announces Pfizer Inc. (NYSE: PFE) as a partner to the Milner Therapeutics Consortium. Pfizer has agreed to join the Consortium, which enables the efficient transfer of materials between industry and academia and allocation of funds for partnering opportunities in Cambridge. Dr Ron Newbold, Vice President, External R&D Innovation at Pfizer, will join the Milner Innovation Board alongside representatives from Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune, University of Cambridge, Babraham Institute and Sanger Institute.

The Milner Therapeutics Consortium acts as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge and was established in 2015. The Consortium brings together the drug development capability of pharmaceutical companies with the know-how of entire academic institutions in Cambridge and has been specifically modelled to help facilitate the speedy exchange of resources and information between partners through a pre-signed agreement. Company partners are able to work individually with academics or through joint activities in order to help accelerate drug development. The Consortium’s Innovation Board includes companies and academic partners and is responsible for overseeing the strategic direction, collective research funding and collaborative activities.

Commenting on the announcement, Prof Tony Kouzarides, founder and director of the Milner Therapeutics Institute said: “We are building the foundations for a world-leading ecosystem for therapeutics research around the Milner Therapeutics Institute. We are delighted that Pfizer has joined the Consortium to develop mutually-beneficial collaborations with Cambridge academics and the Milner Therapeutics Institute. We are focussed on working with Pfizer to advance disease understanding and make a difference to therapies in the clinic.”

Dr Ron Newbold, Vice President, External R&D Innovation at Pfizer, added: “We are pleased to be able to join the Milner Therapeutics Consortium and look forward to a deeper engagement in the Cambridge ecosystem. The UK has a very strong academic and biotech community, and we anticipate working with many world-class scientists that will be supported and inspired by the work of the Milner Institute in the coming years.”

The Milner Therapeutics Institute is a fully integrated institute within the University of Cambridge. The Consortium is seeking academic and industrial partners to work in all therapeutics areas. For further information on how to join the consortium, please contact info@milner.cam.ac.uk.

 

University of Cambridge/Charles River Roadshow

last modified Mar 10, 2017 07:54 PM

Scientists from throughout Cambridge University attended a roadshow supported by Charles River Laboratories to discuss projects that may have drug discovery potential. Click here to see the programme and some pictures from the event. The roadshow was a collaboration between Charles River Laboratories, the Milner Therapeutics Institute, the Office of Translational Research and the Bioscience Impact Team.

Download the meeting agenda here

2016 12 05 13.10.352016 12 05 13.11.06DSC 0836DSC 0843DSC 0842DSC 0836

Milner Therapeutics Symposium - 17 November 2016

last modified Mar 10, 2017 07:53 PM
The inaugural Milner Therapeutics Symposium, From Basic Research to Drugs in Patients, was held on 17 November 2016 at St. Catharine’s College, Cambridge. Due to popular demand, talks were also live-streamed to a second venue at Homerton College. The inaugural Milner Therapeutics Symposium was an opportunity for scientists from academia and industry to discuss the latest research in Cambridge and how it could be applied in the pharma and biotech industry to develop new treatments. The Symposium brochure can be downloaded here and contains abstracts from the speakers and the poster session. There is also a short introduction and contact details for all the Milner Affiliated companies, as well some photographs from the day.

Download the symposium booklet here

IMG 0354IMG 0852IMG 1158MilnerSymp16TwitterIMG 0350

IMG 1125 IMG 1039IMG 1122

New partnership with Japanese Pharmaceutical Company, Shionogi

last modified Jun 12, 2016 09:16 PM
Press Release Cambridge, 13 June 2016 - Shionogi joins Consortium members Astex, AstraZeneca, GlaxoSmithKline

Shionogi’s first research consortium outside Japan and first major research investment in the UK

Cambridge, 13 June 2016 – The Milner Therapeutics Consortium, the outreach programme of the Milner Therapeutics Institute, today announces Shionogi as a new partner joining the consortium. Dr Takeshi Shiota, Senior Vice President, Pharmaceutical Research Division at Shionogi has joined the consortium’s Innovation Board along with representatives from other consortium members Astex, AstraZeneca, GlaxoSmithKline, University of Cambridge, Babraham Institute and Sanger Institute. 

The Milner Therapeutics Consortium acts as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge and was established in 2015. The consortium brings together the drug development capability of pharmaceutical companies with the know-how of entire academic institutions in Cambridge and has been specifically modelled to facilitate the speedy exchange of resources and information between partners through a pre-signed agreement. Company partners are able to work individually with academics or through joint activities in order to accelerate drug development. The consortium’s Innovation Board includes companies and academic partners and is responsible for overseeing the strategic direction, collective research funding and collaborative activities.

In the last two months, 18 companies have become affiliated with the Milner Therapeutics Institute including Charles River Laboratories.

Commenting on the announcement, Prof Tony Kouzarides, founder and director of the Milner Therapeutics Institute and Consortium said: “We are building the foundations for a world-leading hub in Cambridge around the Milner Therapeutics Institute. We are very pleased that Shionogi has become a consortium partner demonstrating that the consortium works on a truly global scale and that companies can collaborate with scientists in Cambridge even if they do not have research sites in the UK. Momentum is gathering around the Institute as eighteen companies, including Charles River Laboratories, have become affiliated in the last few weeks and we have interest from many more.” 

Dr Takeshi Shiota Senior Vice President, Pharmaceutical Research Division at Shionogi added: “The Milner Therapeutics Consortium offers access to exceptional science and collaborative opportunities at Cambridge University, and we are delighted to join as a founding member. This is the first research consortium that we have joined outside Japan and our first major research investment in the UK. 

“Shionogi is one of the oldest research based pharmaceutical companies in Japan, founded in 1878. With research as the number one priority, we have discovered a number of innovative and life-saving medicines such as rosuvastatin (Crestor) and dolutegravir (Tivicay). In Japan, we are the leading proponent of open academic collaboration and have set up alliances with a number of national universities.”

The Consortium is seeking academic and industrial partners. They will be holding an annual Milner Therapeutics Symposium to showcase the latest research and bring academia and industry together. Prof Tony Kouzarides will also be giving a series of short talks around Cambridge to highlight opportunities for academics to collaborate with pharmaceutical and biotech companies, facilitated by the Milner Institute. The talks will be followed by informal networking. 

20 June 2016 - 4pm Lecture Theatre, Department of Pharmacology, central Cambridge

22 June 2016 - 12pm C303, Wellcome Trust Sanger Institute

23 June 2016 - 4pm Lecture Theatre, CRUK Cambridge Institute, Li Ka Shing Centre, Biomedical Campus

29 June 2016 - 4pm Brian Heap Seminar room, Babraham Research Campus

For further information on how to join the consortium, please contact info@milner.cam.ac.uk.

Milner Therapeutics Institute - talks around Cambridge

last modified Jan 20, 2017 08:28 PM
Talks in Cambridge on the Milner Therapeutics Institute
Milner Therapeutics Institute - talks around Cambridge

Capella Building

In 2016 Professor Tony Kouzarides gave a series of short talks around Cambridge to highlight opportunities for academics to collaborate with pharmaceutical and biotech companies, facilitated by the Milner Institute.

20th June 2016 - 4pm Lecture Theatre, Department of Pharmacology, Tennis Court Rd, central Cambridge 
22nd June 2016 - 12pm C303, Wellcome Trust Sanger Institute
23rd June 2016 - 4pm Lecture Theatre, CRUK Cambridge Institute, Li Ka Shing Centre, Biomedical Campus
29th June 2016 - 4pm Brian Heap Seminar room, Babraham Research Campus

 

Download information and posters

Click on the date to see and download the advertising poster for 20 June22 June, 23 June, 29 June.

Click here for more detail on the talk.

Please with any questions.

 

       

        

 

       

 

 

 

 

 

 

 

  

 

 

   

 

 

 

 

 

 

 

 

 

 

 

 

        See Affiliated Companies